MIR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and Src

Cancer Research

Volumn 75, Issue 24, 2015, Pages 5309-5317

  Shi, Xu Bao ^a   Ma, Ai Hong ^a   Xue, Lingru ^a   Li, Meimei ^a   Nguyen, Hao G ^b   Yang, Joy C ^a   Tepper, Clifford G ^a,c   Gandour Edwards, Regina ^a   Evans, Christopher P ^a,c   Kung, Hsing Jien ^a,c   De Vere White, Ralph W ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; MICRORNA 124; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; ISOPROTEIN; MICRORNA; MIRN124 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICRORNAS; POLYCOMB REPRESSIVE COMPLEX 2; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955496300     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0795     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014;120:818-23.
3. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 2014;40:426-33.
4. Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3:1245-53.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
6. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
7. Ning YM, Pierce W, Maher VE, Karuri S, Tang SH, Chiu HJ, et al. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 2013;19:6067-73.
8. Nelson WG, Yegnasubramanian S. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov 2013;3:971-4.
9. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009;19:92-105.
10. Thomson DW, Bracken CP, Goodall GJ. Experimental strategies for micro-RNA target identification. Nucleic Acids Res 2011;39:6845-53.
11. Cortez MA, Ivan C, Zhou P, Wu X, Ivan M, Calin GA. microRNAs in cancer: from bench to bedside. Adv Cancer Res 2010;108:113-57.
12. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010;70:7027-30.
13. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9.
14. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L, Garate L, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confersapoor prognosisinacute lymphoblastic leukemia. Cancer Res 2009;69:4443-53.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agad-janyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-8.
16. Shi XB, Xue L, Ma AH, Tepper CG, Gandour-Edwards R, Kung HJ, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013;32:4130-8.
17. Hellwinkel OJ, Sellier C, Sylvester YM, Brase JC, Isbarn H, Erbersdobler A, et al. A cancer-indicative microRNA pattern in normal prostate tissue. Int J Mol Sci 2013;14:5239-49.
18. Marcias G, Erdmann E, Lapouge G, Siebert C, Barthelemy P, Duclos B, et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat 2010; 31:74-80.
19. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013;73:483-9.
20. Sirotnak FM, She Y, Lee F, Chen J, Scher HI. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may havea roleinthe treatment ofboth androgen-dependent and androgen-independent human prostate cancer. Clin Cancer Res 2002;8:3870-6.
21. Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011;71:5214-24.
22. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, et al. Micro-RNA-125b is a novel negative regulator of p53. Genes Dev 2009;23: 862-76.
23. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011;71:538-49.
24. Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013;34:713-22.
25. Schwabe RF, Wang TC. Targeting liver cancer: first steps toward a miRacle? Cancer Cell 2011;20:698-9.
26. Xia J, Wu Z, Yu C, He W, Zheng H, He Y, et al. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J Pathol 2012;227:470-80.
27. Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer 2013;108:131-8.
28. Vazquez I, Maicas M, Marcotegui N, Conchillo A, Guruceaga E, RomanGomez J, et al. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia. Proc Natl Acad Sci U S A 2010;107:E167-8; author reply E9-70.
29. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res 2013;73:3913-26.
30. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013;4:331-41.
31. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012;338:1465-9.
32. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
33. Cai H, Babic I, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011;71: 862-72.
34. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation ofandrogen receptorina new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009;69:151-60.
35. Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 2014; 33:3140-50.
36. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011;71: 2108-17.
37. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013;172:962-74.
38. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007;104: 19983-8.
39. Amir S, Ma AH, Shi XB, Xue L, Kung HJ, Devere White RW. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One 2013;8:e61064.
40. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2014;33:2495-503.
41. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 2012;7:e32832.
42. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011;71:1656-67.